Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] The clinical challenge of disappearing stents

Drug-eluting stents have become the standard of care for patients undergoing percutaneous coronary intervention.1 Initial concerns about late stent thrombosis with first-generation drug-eluting stents were largely mitigated by the technological advances of the second generation.2 Rates of restenosis and thrombosis with these newer generation stents are impressively low in the first year of use.2 Yet this type of system has disadvantages, including impaired coronary vasomotion, development of early neoatherosclerosis, and long-term retention of a polymer-coated metallic cage, which in some cases might preclude bypass grafting of failed stented segments.